Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study

Pharmacy World and Science

Volumn 29, Issue 6, 2007, Pages 661-670

  Chen, Li Chia ^a   Ashcroft, Darren M ^a   Elliott, Rachel A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Budget; Decision making; Economic evaluations; Health economics; Medicine management committee; United Kingdom

Indexed keywords

ARTICLE; BUDGET; DECISION MAKING; ECONOMIC EVALUATION; HEALTH ECONOMICS; HOSPITAL MANAGEMENT; HUMAN; INTERVIEW; MANAGEMENT; PHARMACIST; QUALITATIVE ANALYSIS; UNITED KINGDOM;

BUDGETS; COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; ECONOMICS, HOSPITAL; HUMANS; MEDICATION SYSTEMS, HOSPITAL; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; QUALITATIVE RESEARCH;

EID: 35348823689     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9125-z     Document Type: Article

References (26)

1. Duthie T, Trueman P, Chancellor J, Diez L. Research into the use of health economics in decision making in the United Kingdom-Phase II. Is health economics 'for good or evil'? Health Policy 1999;46(2):143-57.
2. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. Reference N0515. London: National Institute for Clinical Excellence; 2004.
3. Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee including major submissions involving economic analysis. Canberra: Australian Government Publishing Services; 2002.
4. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Ontario: Ministry of Health; 1994.
5. Johannesson M. Economic evaluation of drugs and its potential uses in policy making. Pharmacoeconomics 1995;8(3):190-8.
6. Drummond M, Cooke J, Walley T. Economic evaluation under managed competition: evidence from the U.K Soc Sci Med 1997;45(4):583-95.
7. Wise J. Report lays out strategy to end "postcode prescribing". Brit Med J 2000;320(7241):1027a.
8. Jenkings KN, Barber N. What constitutes evidence in hospital new drug decision-making? Soc Sci Med 2004;58(9):1757-66.
9. Walley T, Barton S, Cooke J, Drummond M. Economic evaluations of drug therapy: attitudes of primary care prescribing advisers in Great Britain. Health Policy 1997;41(1):61-72.
10. Lavis JN, Ross SE, Stoddart GL, Hohenadel JM, McLeod CB, Evans RG. Do Canadian civil servants care about the health of populations? Am J Public Health 2003;93(4):658-63.
11. Lavis JN, Robertson D, Woodside JM, McLeod CB, Abelson J. How can research organizations more effectively transfer research knowledge to decision makers? Milbank Q 2003;81(2):221-2.
12. Coyle D. Increasing the impact of economic evaluation on health-care decision-making. Centre for Health Economic Discussion Paper 108 ed. England: University of York; 1993.
13. Mays N, Pope C. Qualitative research: observational methods in health care settings. BMJ 1995;311(6998):182-4.
14. Britten N. Qualitative interview in health care research. In: Pope C, Mays N, editors. Qualitative research in health care. 2nd ed. London: BMJ Books; 2000. p. 11-8.
15. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ 2000;320(7227):114-6.
16. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, editors. Analyzing qualitative data. London: Routledge; 1994. p. 174-94.
17. Thorne S. Data analysis in qualitative research. ENB Notebook 2000;3:68-70.
18. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 2004;329(7472):972-5.
19. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70.
20. Hillman A, Eisenberg JM, Pauly MV. Avoiding bias in the conduct of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991;324:1362-5.
21. Friedberg M, Saffron B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999;282(15):1453-7.
22. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005;43(7 Suppl):5-14.
23. Drummond MF, McGuire A. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2001.
24. Bryan S, Brown J. Extrapolation of cost-effectiveness information to local settings. J Health Serv Res Policy 1998;3(2):108-12.
25. UKPDS Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ 1998;317(7160):720-6.
26. Sculpher MJ, Poole L, Cleland J, Drummond M, Armstrong PW, Horowitz JD, et al. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. Eur J Heart Fail 2000;2(4):447-54.